AstraZeneca has announced that the randomized clinical trials of AZD1222, a vaccine developed Oxford, has been paused because of the safety concerns. A single event of illness has been reported, and an independent committee will review the safety data.
AstraZeneca has announced that it a ‘routine’ action and is working to progress on the review of the single event to minimize the impact of the single event of illness on the trial timeline.
“At AstraZeneca, we put science, safety, and the interests of society at the heart of our work. This temporary pause is living proof that we follow those principles while a single event at one of our trial sites is assessed by a committee of independent experts.” said Pascal Soriot, Chief Executive Officer
The University of Oxford and Vaccitech invented AZD1222. The vaccine uses a replication-deficient chimpanzee viral vector, which contains the SARS-CoV-2 virus spike protein genetic material. Once the vaccine gets injected into the body, it stimulates the immune response by the body.
For pipeline, market overview, and market access reports (syndicate and customized) please write to sales@firstviewinsight.com
For all syndicate reports: Click here